Aleafia Health Helps Patients & Investors with Revenue Generating Research
February 7th, 2019
Exclusive, News, Top News
Medical cannabis research is only starting to scratch the surface of how cannabinoids could play a role in areas traditionally dominated by prescription pharmaceuticals. Given the massive size of the pharmaceutical industry, these insights could translate to significant value for first-movers in large indications. The problem is that there’s limited data given the newness and fragmentation of the global cannabis industry.
Aleafia Health Inc. (TSX-V: ALEF) (OTC: ALEAF) (FRA: ARAH) is well-equipped to study the effects of cannabis with its wholly-owned network of more than 20 Canabo Medical Clinics with over 50,000 patients. These clinics provide the company with the largest medical cannabis dataset in the world, enabling researchers to validate cannabis sciences, product teams to develop innovative new products, and management to build a strong IP portfolio. Aleafia Health’s research division generated $612,000 in revenue in Q3 2018, and the Company is building on that success.
Advancing Cannabis Research
Aleafia Health’s two largest clinical studies were its benzodiazepine study published earlier this year and its sleep study that began in September of last year. These studies are just starting to scratch the surface of what’s possible with the company’s massive clinical presence and expert teams of physicians and researchers. Many cannabis companies are eager to gather the data needed to support their medical products.
The company recently published a retrospective study that looked at benzodiazepine use among medical cannabis patients. Researchers found that 45.2 percent of patients regularly consuming benzodiazepines had stopped taking the medication within about six months of becoming medical cannabis patients at its Canabo Medical Clinics. The results were published in the peer-reviewed journal, Cannabis and Cannabinoid Research in January.
In September, the company initiated a joint medical cannabis study to improve the management and treatment of insomnia and daytime sleepiness with the Cronos Group Inc. (NYSE: CRON). The company formally launched Aleafia Labs during the following month as a way to formalize its research activities using its existing patient database and intellectual property, with a focus on addicting prescription opioids and sleeping aids.
Leveraging Big Data Insights
The launch of Aleafia Labs enabled Aleafia Health to institutionalize its research offerings. By tracking all patient interactions, the company generates significant datasets that are hosted on Amazon AWS and visualized with Google Data Studio. During the third quarter, the company generated $600,000 in revenue from these research offerings, primarily from medical cannabis companies subscribing to its proprietary medical cannabis patient dataset.
Earlier this month, the company hired a Product Data Science Fellow, Dr. Graham Merry, MD, to lead its evidence-based product research efforts by leveraging its proprietary ten million point patient dataset following its recent acquisition of a licensed producer. Current research efforts include partnerships with Cronos Group, Guided 420 Genetics, and AKESOgen, which could result in meaningful insights for patients and physicians over the coming months.
“I have been tremendously impressed with the whole team at Aleafia while working in this field,” said Dr. Merry. “This initiative will allow the opportunity to obtain clinical evidence to validate and gain wider acceptance in the medical community realizing the benefits of cannabinoid treatment in serious and debilitating disease. Together we will make a huge difference in addressing the unmet needs of patients in this emerging field of medicine.”
Aleafia Health Inc. (TSX-V: ALEF) (OTC: ALEAF) (FRA: ARAH) is well positioned to advance cannabinoid science with its massive medical cannabis patient datasets and leading team of researchers. In addition to generating revenue from research activities, the company will leverage these insights to develop and launch its own evidence-based cannabis products targeting a wide range of indications, including pain management and sleep.
For more information, visit the company’s website at https://www.aleafiainc.com/invest/
Click Here to Download Aleafia Health Inc.’s Investor Presentation
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.